Instil Bio shares are trading higher after Baird maintained an Outperform rating on the stock and raised its price target from $32 to $180.
Portfolio Pulse from Benzinga Newsdesk
Instil Bio shares surged after Baird maintained an Outperform rating and significantly raised its price target from $32 to $180.
September 13, 2024 | 6:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Instil Bio's stock price is likely to rise in the short term due to Baird's increased price target from $32 to $180 and maintained Outperform rating.
The significant increase in the price target from $32 to $180 by Baird, along with the maintained Outperform rating, suggests strong confidence in Instil Bio's future performance. This is likely to attract investor interest and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100